Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q3 CY2025 results exceeding the market’s revenue expectations , with sales up 2.2% year on year to $249.3 million. Its GAAP loss of $0.31 per share was 3.6% above analysts’ consensus estimates. Is now the time to buy Tandem Diabetes? Find out in our full research report. Tandem Diabetes (TNDM) Q3 CY2025 Highlights: Revenue: $249.3 million vs analyst estimates of $236 million (2.2% year-on-year growth, 5.6% beat) EPS (GAAP): -$0.31 ...